Celcuity (NASDAQ:CELC) Trading 8% Higher After Strong Earnings

Celcuity, Inc. (NASDAQ:CELC)’s share price traded up 8% during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $135.53 and last traded at $134.44. 509,765 shares changed hands during trading, a decline of 37% from the average session volume of 810,381 shares. The stock had previously closed at $124.47.

The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity announced amendments to its Phase 3 VIKTORIA-2 trial for gedatolisib, expanding the study to include endocrine-sensitive patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The broader trial population could increase the drug’s commercial opportunity if results remain positive. Article Title
• Positive Sentiment: Needham & Company reiterated its Buy rating on Celcuity and raised its price target to $157, signaling continued analyst confidence in the company’s pipeline and upside potential. Article Title
• Positive Sentiment: Celcuity reported first-quarter 2026 earnings of ($0.97) per share, beating consensus estimates of ($1.07). While the company is still unprofitable, the smaller-than-expected loss likely supported investor sentiment. Article Title
• Neutral Sentiment: Celcuity also provided its first-quarter financial results and a corporate update, but the main market focus appears to be on the trial expansion and analyst upgrades rather than the broader financial details. Article Title
• Neutral Sentiment: An earnings call transcript was published for the quarter, which may help investors assess management’s commentary on trial progress, cash needs, and commercialization plans. Article Title

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a report on Monday, May 4th. Wells Fargo & Company raised their price target on shares of Celcuity from $150.00 to $183.00 and gave the company an “overweight” rating in a report on Friday. Craig Hallum reaffirmed a “buy” rating and set a $189.00 price target on shares of Celcuity in a report on Monday, May 4th. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a report on Monday, May 4th. Finally, Wolfe Research reissued an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $140.20.

Insider Buying and Selling

In related news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently modified their holdings of CELC. SummitTX Capital L.P. raised its position in shares of Celcuity by 54.7% during the 1st quarter. SummitTX Capital L.P. now owns 20,812 shares of the company’s stock valued at $2,375,000 after purchasing an additional 7,363 shares during the period. ABS Direct Equity Fund LLC bought a new stake in shares of Celcuity during the 1st quarter valued at $171,000. Granahan Investment Management LLC raised its position in shares of Celcuity by 2.1% during the 1st quarter. Granahan Investment Management LLC now owns 88,833 shares of the company’s stock valued at $10,139,000 after purchasing an additional 1,801 shares during the period. Gabelli Funds LLC bought a new stake in shares of Celcuity during the 1st quarter valued at $228,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after purchasing an additional 86 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Up 2.2%

The stock has a market capitalization of $6.66 billion, a P/E ratio of -35.30 and a beta of 0.09. The company’s 50-day moving average price is $118.86 and its 200 day moving average price is $106.73. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.